FDA group model in R [Two-Stage / GS Designs]

posted by VStus – Poland, 2016-10-20 13:57 (1549 d 05:47 ago) – Posting: # 16745
Views: 29,375

Dear Maestro,

» I actually lost a bit track of this discussion and I am not exactly sure what the comparisons try to achieve?!?

I'm sorry for confusion. I accept that I for sure may understood this topic completely wrong. I just wanted to address Myttiry's issue of non-similar results between R's lm() and WiNonlin in assessment of the FDA group model 1 and 2 for unbalanced dataset.

I don't have access to SAS or WiNonlin, but I have some study reports assessed via SAS using FDA's group model 1 and 2. So, in regards to Point Estimates, 90% CIs, F and P values for:
FDA Group 1 Group*Treat #Treat:Group in my R output
FDA Group 2
- Treat #Drug in my R output
- Per(Group) # group:prd in my R output
- Subj(Group*Seq) # seq:subj in R
lm() provides same results as PROC GLM

If Russian Authorities require an additional assessment using a group model, R output should be ok. So as PHX, if PE and 90%CI are not calculated using FDA Group Model 1.

Regards,
VStus

Complete thread:

Activity
 Admin contact
21,303 posts in 4,441 threads, 1,487 registered users;
online 3 (0 registered, 3 guests [including 3 identified bots]).
Forum time: Saturday 18:44 CET (Europe/Vienna)

If you can’t solve a problem, then there is an easier problem
you can solve: find it.    George Pólya

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5